Comparative effectiveness of dexamethasone versus methylprednisolone for neuropathic outcomes after combined spinal-epidural labor analgesia: a prospective, randomized, double-blind trial

地塞米松与甲泼尼龙在联合脊髓硬膜外分娩镇痛后神经性疼痛结局方面的疗效比较:一项前瞻性、随机、双盲试验

阅读:1

Abstract

BACKGROUND: Paresthesias occurring during combined spinal-epidural labor analgesia due to needle puncture or epidural catheter placement may lead to nerve injury. We compared the effects of epidural dexamethasone versus methylprednisolone on neurological outcomes. METHODS: In this prospective, randomized, double-blind clinical trial conducted at a Chinese obstetrics hospital, parturients who developed paresthesias during combined spinal-epidural labor analgesia due to needle puncture or epidural catheter placement were randomized to receive an epidural injection of dexamethasone (5 mg) or methylprednisolone (40 mg). The primary outcome was neurological function at 14 days postpartum, including impaired skin sensation, decreased muscle strength, or other neurological symptoms. Secondary outcomes included adverse events and changes in inflammatory biomarkers. RESULTS: A total of 315 parturients were randomized and completed the study. At 14 days postpartum, the neurological function outcomes did not differ significantly between the two groups (p > 0.05). Among the secondary outcomes, the dexamethasone group had a higher incidence of epidural-related maternal fever (ERMF) (7.6% vs. 2.5%, p < 0.05), and the 24-h postpartum serum Interleukin-6 (IL-6) level was significantly higher than that in the methylprednisolone group [26.1 (18.2-38.9) pg./mL vs. 15.4 (13.2-17.6) pg./mL, p < 0.05]. There were no significant differences between the two groups in postpartum hemorrhage, nausea and vomiting, instrumental delivery rate, Neonatal Intensive Care Unit (NICU) admission rate, or 24-h postpartum serum C-reactive protein (CRP) level (p > 0.05). CONCLUSION: In parturients who developed paresthesia during combined spinal-epidural labor analgesia, epidural administration of dexamethasone or methylprednisolone resulted in comparable neurological outcomes at 14 days postpartum. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/, identifier ChiCTR2300078866.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。